Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Impact of artificial intelligence on the availability, accessibility, acceptability and quality of ophthalmic disease screening services: a scoping review
0
Zitationen
11
Autoren
2025
Jahr
Abstract
This scoping review examines the existing literature on the application of artificial intelligence (AI) in screening for eye diseases, with a focus on evaluating whether AI-assisted diagnostic technologies enhance the availability, accessibility, acceptability and quality of screening services. 42 original studies were selected for in-depth analysis, including those employing health economic evaluations. Methodological quality was assessed using the Mixed Methods Appraisal Tool, with the majority of studies demonstrating high quality-24 scored 5/5, 15 scored 4/5 and the rest scored 3/5. Among the included studies, 34 compared manual screening with either AI-assisted or fully AI-driven approaches. Availability was the most frequently studied aspect (28 studies), followed by acceptability (12 studies), whereas accessibility and service quality were less commonly addressed. Overall, AI shows significant potential to improve the cost-effectiveness of eye care services and enhance patient access, particularly in remote or underserved regions. It was also well-accepted by patients, with high satisfaction and improved referral compliance. The findings suggest that AI holds promise for advancing eye disease screening, although large-scale, long-term trials are needed to effectively integrate AI into the reconstruction of screening processes and the reshaping of eye health service systems.
Ähnliche Arbeiten
Optical Coherence Tomography
1991 · 13.568 Zit.
Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs
2016 · 7.206 Zit.
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
2014 · 6.679 Zit.
YOLOv3: An Incremental Improvement
2018 · 5.881 Zit.
Ranibizumab for Neovascular Age-Related Macular Degeneration
2006 · 5.794 Zit.
Autoren
Institutionen
- Tongji University(CN)
- Shanghai Eye Disease Prevention & Treatment Center(CN)
- Shanghai Jiao Tong University(CN)
- Shanghai First People's Hospital(CN)
- Centre for Eye Research Australia(AU)
- Shanghai Municipal Center For Disease Control Prevention(CN)
- Zoucheng People's Hospital(CN)
- Yangpu Hospital of Tongji University(CN)
- Hong Kong Polytechnic University(HK)